VR
Viridian Therapeutics, Inc.
VRDN · NASDAQ
$21.24 -5.31% (-$1.19)
1M -2.58%
Market Cap $2.53B
P/E Ratio -
Div. Yield -
ROE 61.35%
Bulios Fair Price
$27.2
28.1% upside
Current Price
$21.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VRDN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
27 /100
Expensive P/S 35.50x
P/B 3.81x
P/E N/A
Growth
100 /100
Growing Rev. growth 241.95%
Book val. growth 22.27%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 99.38%
FCF margin 471.04%
Net margin 544.06%
Quality
1 /100
Poor ROIC 39.18%
Asset turnover 0.06x
ROE 61.35%
Debt
66 /100
Moderate Debt/Equity 0.37x
Int. coverage -19.77x
Current ratio 16.95x
Stability
42 /100
Moderate Beta 0.96x
Profitable years 0
Rev. volatility 13,511.78%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VRDN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen F. Mahoney
Employees
252
Headquarters
Waltham
Upcoming events
04 NOV
Earnings
Upcoming earnings report